Molecular Cytogenetics Market Report by Product Type, Technology (Comparative Genomic Hybridization, Fluorescence in SITU Hybridization, Immunohistochemistry, Karyotyping, and Others), Application, End User, and Region 2024-2032
세계 분자세포 유전학 시장 규모는 2023년 27억 달러에 달했습니다. 향후 IMARC 그룹은 2032년까지 시장 규모가 60억 달러에 달하고, 2024-2032년간 9.1%의 연평균 성장률(CAGR)을 나타낼 것으로 예측했습니다.
분자세포 유전학은 데옥시리보핵산(DNA) 메커니즘에 대한 생의학 연구를 말하며, 유전적 돌연변이 및 장애를 연구합니다. DNA 증폭, DNA 분리, 유전자 스크리닝, 가상 핵형 분석, 형광 in situ hybridization(FISH)과 같은 기술은 DNA 프로브를 사용하여 유전체과 표적 영역을 시각화하기 위해 DNA 프로브를 사용합니다. DNA 프로브를 이용하여 유전체과 그 표적 영역을 시각화 및 표지함으로써 분자세포 유전학에 일반적으로 사용되고 있습니다. 이러한 기술은 다양한 악성 종양 및 혈액 악성 종양의 진단 및 치료에 매우 유용합니다.
암 및 기타 유전성 질환의 유병률 증가, 노인 인구 증가는 시장 성장을 가속하는 중요한 요인 중 하나입니다. 분자세포 유전학은 주로 질병 특성 예측 모델과 효과적인 치료 전략 개발에 활용되고 있습니다. 또한, 암 치료를 위한 표적 치료의 광범위한 채택은 시장 성장을 가속하고 있으며, FISH 및 비교 유전체 혼성화(CGH)는 암의 진행 단계를 분석하고 환자에게 맞춤형 치료를 제공하기 위한 약리학적 유전체 바이오마커 연구에도 사용되고 있습니다. 또한, 개선된 소모품, 시약, 소프트웨어, 키트 개발 등 다양한 기술 발전이 또 다른 성장 촉진요인으로 작용하고 있습니다. 이러한 발전은 복제 가능하고 정확하며 신뢰할 수 있는 임상병리 검사 결과를 생성하는 데 도움이 되고 있습니다. 이 밖에도 의료 인프라가 크게 개선되고, 바이오메디컬 과학 부문의 광범위한 조사 개발(R&D) 활동이 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 다룬 주요 질문들
- 2023년 세계 분자세포 유전학 시장 규모는?
- 2024-2032년 세계 분자세포 유전학 시장의 예상 성장률은?
- 코로나19가 세계 분자세포 유전학 시장에 미치는 영향은?
- 세계 분자세포 유전학 시장을 이끄는 주요 요인은?
- 세계 분자세포 유전학 시장의 제품 유형별 분류는?
- 세계 분자세포 유전학 시장의 기술별 시장 현황은?
- 세계 분자세포 유전학 시장의 용도별 시장 현황은?
- 세계 분자세포 유전학 시장의 최종 사용자별 분석은?
- 세계 분자세포 유전학 시장의 주요 지역은?
- 세계 분자세포 유전학 시장의 주요 진출 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 분자세포 유전학 시장
- 시장 개요
- 시장 분석
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 제품 유형별
제7장 시장 분석 : 기술별
- Comparative Genomic Hybridization
- Fluorescence in SITU Hybridization (FISH)
- Immunohistochemistry
- Karyotyping
- 기타
제8장 시장 분석 : 용도별
제9장 시장 분석 : 최종사용자별
- 임상 연구실
- 병원 및 병리학 연구소
- 제약 기업 및 바이오테크놀러지 기업
- 기타
제10장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter의 Five Forces 분석
- 개요
- 바이어의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 진출업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Abbott Laboratories
- Agilent Technologies Inc.
- Applied Spectral Imaging Inc.
- Biological Industries
- Bio-RAD Laboratories Inc.
- BioView Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Illumina Inc.
- Oxford Gene Technology
- Perkinelmer Inc.
- Quest Diagnostics Incorporated
LSH
The global molecular cytogenetics market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.0 Billion by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032.
Molecular cytogenetics refers to the biomedical research of deoxyribonucleic acid (DNA) mechanisms to investigate genetic mutations and disorders. It studies the structural and functional organization of the chromosomes and their nucleus, genomic variations, expression, evolution and abnormalities, especially in medicinal and cancer-related genetics. Techniques such as DNA amplification, DNA isolation, gene screens, virtual karyotyping and fluorescence in situ hybridization (FISH) are commonly used for molecular cytogenetics by using DNA probes to visualize and label the genome or its targeted regions. These techniques are highly beneficial in the diagnosis and treatment of various malignant tumors and hematological malignancies.
The increasing prevalence of cancer and other genetic disorders, along with the rising geriatric population, is one of the key factors driving the growth of the market. Molecular cytogenetics is primarily being used for developing predictive models of disease traits and effective treatment strategies. Furthermore, the widespread adoption of targeted therapies for cancer treatment is also augmenting the market growth. FISH and Comparative Genomic Hybridization (CGH) are also used for pharmacogenomic biomarker studies to analyze cancer progression stages and provide personalized treatment to the patient. Additionally, various technological advancements, such as the development of improved consumables, reagents, software and kits, are acting as other growth-inducing factors. These advancements aid in generating duplicatable, accurate and reliable clinical-pathological test results. Other factors, including significant improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biomedical sciences, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global molecular cytogenetics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, technology, application and end user.
Breakup by Product Type:
Instruments
Consumables
Software and Services
Others
Breakup by Technology:
Comparative Genomic Hybridization
Fluorescence in SITU Hybridization (FISH)
Immunohistochemistry
Karyotyping
Others
Breakup by Application:
Genetic Disorders
Oncology
Personalized Medicine
Others
Breakup by End User:
Clinical and Research Laboratories
Hospitals and Pathology Laboratories
Pharmaceutical and Biotechnology Companies
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging Inc., Biological Industries, Bio-RAD Laboratories Inc., BioView Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina Inc., Oxford Gene Technology, Perkinelmer Inc. and Quest Diagnostics Incorporated.
Key Questions Answered in This Report
- 1. What was the size of the global molecular cytogenetics market in 2023?
- 2. What is the expected growth rate of the global molecular cytogenetics market during 2024-2032?
- 3. What has been the impact of COVID-19 on the global molecular cytogenetics market?
- 4. What are the key factors driving the global molecular cytogenetics market?
- 5. What is the breakup of the global molecular cytogenetics market based on the product type?
- 6. What is the breakup of the global molecular cytogenetics market based on the technology?
- 7. What is the breakup of the global molecular cytogenetics market based on application?
- 8. What is the breakup of the global molecular cytogenetics market based on the end user?
- 9. What are the key regions in the global molecular cytogenetics market?
- 10. Who are the key players/companies in the global molecular cytogenetics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Molecular Cytogenetics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Instruments
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Consumables
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Software and Services
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Technology
- 7.1 Comparative Genomic Hybridization
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Fluorescence in SITU Hybridization (FISH)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Immunohistochemistry
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Karyotyping
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Application
- 8.1 Genetic Disorders
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Oncology
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Personalized Medicine
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by End User
- 9.1 Clinical and Research Laboratories
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Hospitals and Pathology Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Pharmaceutical and Biotechnology Companies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Agilent Technologies Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Applied Spectral Imaging Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Biological Industries
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Bio-RAD Laboratories Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 BioView Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 Danaher Corporation
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 F. Hoffmann-La Roche AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 SWOT Analysis
- 15.3.9 Illumina Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Oxford Gene Technology
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.11 Perkinelmer Inc.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Quest Diagnostics Incorporated
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
